


What is claimed is:

1. Compounds of the formula (I):



(I)

R<sub>1</sub> is selected from the group consisting of a bond and C<sub>1-10</sub> alkyl, alkenyl or alkenylene;

R<sub>2</sub> and R<sub>3</sub> are independently selected from the group consisting of hydrogen and C<sub>1-10</sub> alkyl, alkenyl or alkenylene

R<sub>4</sub> is selected from the group consisting of a bond and C<sub>1-10</sub> alkyl, alkenyl or alkenylene, said C<sub>1-10</sub> alkyl, alkenyl or alkenylene optionally substituted with 1-3 halogen or oxo groups;

R<sub>5</sub> is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a C<sub>3-12</sub> cycloalkyl;

R<sub>6</sub> is selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>3-12</sub> cycloalkyl and halogen; and

N is an integer from 0-3; and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 wherein R<sub>1</sub> is selected from methyl or ethyl.

3. A compound of claim 1 wherein R<sub>2</sub> is selected from methyl, ethyl, propyl and butyl.

4. A compound of claim 1 wherein R<sub>4</sub> is selected from a bond, methyl or ethyl, wherein the methyl and ethyl are optionally substituted with an oxo group.

5. A compound of claim 1 wherein R<sub>5</sub> is phenyl.

- pub 5
6. A compound of claim 1 selected from  
1-benzylamino-3-dibutylamino-propyl;  
1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-diethylamino-ethyl;  
1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-dibutylamino-ethyl; and  
pharmaceutically acceptable salts thereof.
- pub 3
7. A pharmaceutical composition comprising a compounds of claim 1 and at  
least one pharmaceutically acceptable excipient.
8. A method of treating pain comprising administering to a patient in need  
thereof, an effective amount of a compound according to claim 1.
9. A method of modulating a pharmacological response from the  $\mu$  receptor  
comprising administering an effective amount of a compound according to  
claim 1.
10. A method of reducing side effects associated with the administration of opioid  
analgesics in a human patient comprising administering to said human patient  
an analgesically effective amount of a non-opioid compound which exhibits a  
binding affinity specificity for the  $\mu$  receptor as compared to the  $\delta_2$  receptor  
( $K_i$  (nM) at the  $\delta_2$  receptor/  $K_i$  (nM) at the  $\mu$  receptor) of greater than about  
250.
- add 10  
add 34  
add 54